Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD19-chimeric Antigen Receptor T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Very early researchLooking for participantsNCT04603872
What this trial is testing

CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryAcute Lymphoblastic Leukemia, in Relapse+3 more
Zhejiang University 120
Testing effectiveness (Phase 2)UnknownNCT05651100
What this trial is testing

Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Kecellitics Biotech Company Ltd 50
Testing effectiveness (Phase 2)UnknownNCT05385263
What this trial is testing

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Who this might be right for
B Cell Lymphoma
Tel-Aviv Sourasky Medical Center 20
Early research (Phase 1)Study completedNCT05075603
What this trial is testing

Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy

Who this might be right for
Refractory Diffuse Large B-cell LymphomaRecurrent Diffuse Large B-Cell LymphomaHigh-grade B-cell Lymphoma+2 more
NeoImmuneTech 17
Testing effectiveness (Phase 2)UnknownNCT02644655
What this trial is testing

Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia

Who this might be right for
Recurrent B-Cell TumorRefractory B-Cell Tumor
Second Military Medical University 20
Testing effectiveness (Phase 2)Looking for participantsNCT05326243
What this trial is testing

Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaPrimary Mediastinal Large B Cell LymphomaLarge B-cell Lymphoma+2 more
Pell Bio-Med Technology Co., Ltd. 49
Testing effectiveness (Phase 2)UnknownNCT04553393
What this trial is testing

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Who this might be right for
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
Chinese PLA General Hospital 80
Testing effectiveness (Phase 2)UnknownNCT04782193
What this trial is testing

A Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

Who this might be right for
B Cell Lymphoma
Chongqing Precision Biotech Co., Ltd 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT04429438
What this trial is testing

Multi-CAR-T Cells Targeting B Cell Lymphomas

Who this might be right for
B Cell Lymphoma (BCL)
Shenzhen Geno-Immune Medical Institute 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT03919240
What this trial is testing

CAR-T Cell Therapy Targeting to CD19 for R/R ALL

Who this might be right for
Acute Lymphoblastic Leukemia With Failed Remission
The First Affiliated Hospital of Soochow University 196
Testing effectiveness (Phase 2)Active Not RecruitingNCT04416984
What this trial is testing

Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

Who this might be right for
Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Allogene Therapeutics 160
Early research (Phase 1)Study completedNCT02746952
What this trial is testing

Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Institut de Recherches Internationales Servier 25
Early research (Phase 1)UnknownNCT04296461
What this trial is testing

Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Non-Hodgkin Lymphoma
UWELL Biopharma 20
Testing effectiveness (Phase 2)Study completedNCT04359784
What this trial is testing

Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

Who this might be right for
B-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center 27
Not applicableLooking for participantsNCT07524816
What this trial is testing

Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma

Who this might be right for
Large B-Cell Lymphoma (LBCL)
N.N. Alexandrov National Cancer Centre 76
Early research (Phase 1)Looking for participantsNCT07085104
What this trial is testing

Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Who this might be right for
Systemic Lupus Erythematosus (With and Without Nephritis)Idiopathic Inflammatory MyopathySystemic Sclerosis
Allogene Therapeutics 66
Early research (Phase 1)Study completedNCT04134117
What this trial is testing

Tisagenlecleucel In Primary CNS Lymphoma

Who this might be right for
Primary CNS LymphomaRefractory Primary CNS LymphomaRelapsed Primary CNS Lymphoma
Matthew J. Frigault, M.D. 13
Testing effectiveness (Phase 2)Study completedNCT02132624
What this trial is testing

CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial.

Who this might be right for
B Cell LymphomaB Cell Leukemia
Uppsala University 15
Testing effectiveness (Phase 2)Study completedNCT03994913
What this trial is testing

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma
CARsgen Therapeutics Co., Ltd. 20
Very early researchNot Yet RecruitingNCT07670260
What this trial is testing

GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma

Who this might be right for
Relapsed or Refractory Large B-cell Lymphoma
Chinese PLA General Hospital 9
Next Page